Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases
- PMID: 40822422
- PMCID: PMC12351007
- DOI: 10.1007/s13205-025-04470-8
Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases
Abstract
Neurodegenerative diseases (NDs) such as Alzheimer's, Parkinson's, and Huntington's diseases are characterized by progressive neuronal loss, oxidative stress, neuroinflammation, and cognitive decline. The most prevalent and bioactive catechin in green tea, epigallocatechin-3-gallate (EGCG), has shown promise as a neuroprotective agent because of its many biological properties. The review discusses the potential of EGCG in combating neurodegeneration and cognitive impairments through antioxidant benefits and signaling pathways. Recent advancements in structural analogs, liposomal encapsulation, and nanoformulations have shown potential in improving pharmacokinetics. High dosage safety issues and inter-individual response variability remain significant challenges in the field of medicine. The review emphasizes the importance of structured clinical trials, formulation uniformity, biomarker-guided monitoring, and customized therapy approaches to fully realize EGCG's potential as a neuroprotective drug. EGCG improves autophagic clearance, reduces tau hyperphosphorylation, and inhibits amyloid-beta aggregation, aiding in neuroprotective properties. Early clinical trials suggest it can be used as an adjuvant therapy, and recent advancements in formulation and delivery techniques are promising.
Keywords: Cognitive impairments; Epigallocatechin-3-gallate; Neurodegenerative diseases; Neuroprotection; Oxidative stress.
© King Abdulaziz City for Science and Technology 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Conflict of interest statement
Conflict of interestThe authors declare no conflict of interest.
References
-
- Abubakar M et al (2025) Diabetes, alzheimer’s disease risk factors, and the cafeteria diet: a comprehensive review. Curr Neuropharmacol. 10.2174/011570159X384737250626094315 - PubMed
-
- Ahmad N, Mukhtar H (1999) Green tea polyphenols and cancer: biologic mechanisms and practical implications. Nutr Rev 57(3):78–83 - PubMed
-
- Ahmed R, VanSchouwen B, Jafari N, Ni X, Ortega J, Melacini G (2017) Molecular mechanism for the (−)-epigallocatechin gallate-induced toxic to nontoxic remodeling of Aβ oligomers. J Am Chem Soc 139(39):13720–13734 - PubMed
-
- Aktas O et al (2004) Green tea epigallocatechin-3-gallate mediates T cellular NF-κB inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol 173(9):5794–5800 - PubMed
-
- Ali B et al (2016) In silico analysis of green tea polyphenols as inhibitors of AChE and BChE enzymes in Alzheimer’s disease treatment. CNS Neurol Disord Drug Targets Form Curr Drug Targets-CNS Neurol Disorders 15(5):624–628 - PubMed
Publication types
LinkOut - more resources
Full Text Sources